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Taxane-containing 
induction chemotherapy 
followed by definitive 
chemoradiotherapy
Outcome in patients with locally 
advanced head and neck cancer
Radiotherapy (RT) and concomitant che-
motherapy is currently regarded as the 
standard of care for unresectable locally 
advanced squamous cell carcinoma of the 
head and neck (HNSCC) with an absolute 
improvement of 8% in 5-year survival due 
to concomitant chemotherapy [1]. In or-
der to increase the outcome of patients 
with HNSCC, other attempts such as al-
tered fractionated RT [2, 3] or induction 
chemotherapy have been explored. The 
non-inferiority of induction chemother-
apy followed by RT vs. surgery and post-
operative RT has been demonstrated for 
hypopharyngeal cancer [4]. Recently, the 
addition of taxanes to induction chemo-
therapy was investigated by the trials TAX 
324 (induction chemotherapy followed by 
chemoradiotherapy) and EORTC 24971/
TAX 323 (induction chemotherapy fol-
lowed by RT), which both showed a sur-
vival benefit of docetaxel, cisplatin, and 
fluorouracil (5-FU; TPF) vs. cisplatin and 
5-FU (PF) induction [5, 6]. Acute RT-re-
lated toxicity was deemed equal between 
the two respective treatment arms in both 
studies. Results from a phase II trial in 
 Italy testing TPF induction chemothera-
py followed by chemoradiotherapy vs. di-
rect chemoradiotherapy are available sug-
gesting a possible overall survival (OS) 
benefit for induction chemotherapy with 
similar acute RT-related toxicity rates [7]. 
Results from recently published phase III 
trials comparing induction chemothera-
py with direct chemoradiation or surgery 
plus adjuvant chemoradiation, however, 
failed to demonstrate a survival benefit in 
favor of induction chemotherapy [8, 9, 10].
In our clinic, patients were referred 
for induction chemotherapy in case of 
bulky and/or rapidly progressive prima-
ry tumors or lymph nodes where resec-
tion was not feasible. The intention was to 
treat rapidly local tumor growth and ame-
liorate symptoms like pain and nutrition-
al status. The standard regimen was two 
to three cycles of induction chemothera-
py. To achieve a maximal tumor control, 
concomitant cisplatin was designated as 
systemic agent. We report on the toxicity 
and oncological outcome after induction 
chemotherapy with TPF and chemora-
diotherapy using cisplatin as concomitant 
agent in conjunction with state-of-the-art 
IMRT in patients with bulky tumors.
Patients and methods
Patients and treatment
The data of 40 patients who underwent at 
least one cycle of induction chemotherapy 
and were scheduled for definitive chemo-
radiotherapy between July 2004 and No-
vember 2010 were retrospectively ana-
lyzed. The study was approved by the lo-
cal Ethics Committee. Clinical staging 
was based on radiologic findings as well 
as clinical examination. The case of each 
patient was discussed in an interdisciplin-
ary tumor board. Most patients had bulky 
unresectable disease. In 3 patients with 
smaller but rapidly progressive tumors, 
one cycle of induction chemotherapy was 
given to prevent tumor growth during RT 
planning. Induction chemotherapy con-
sisted of docetaxel at a dose of 75 mg/m2 
followed by cisplatin 75 mg/m2 and fluo-
rouracil 1,000 mg/m2 as continuous infu-
sion for 4 days.
For treatment planning, a dedicated 
computed tomography (CT) scan with in-
travenous contrast material was used. Pa-
tients were immobilized in supine posi-
tion using a thermoplastic mask covering 
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the head and shoulders. Target delineation 
was based on the pre-induction size and 
location of the tumor. We defined two dif-
ferent risk levels of clinical target volume 
(CTV): CTV72 comprised all gross tumor 
with an isotropic margin of  10–12 mm 
and was treated to 72 Gy; CTV54 includ-
ed elective areas and was treated to 54 Gy. 
The resulting CTVs were expanded to 
planning target volumes (PTVs) by add-
ing a symmetric 3-mm margin. The defi-
nition of elective nodal target volumes fol-
lowed the recommendations proposed by 
Eisbruch et al. [11]. The PTVs were treat-
ed sequentially with a fractionation of 5 
times 2 Gy per week. Preferably, two to 
three cycles of cisplatin 100 mg/m2 tri-
weekly was applied as concurrent agent. 
Cetuximab or carboplatin was used alter-
natively. The prophylactic placement of a 
percutaneous endoscopic gastrostomy be-
fore chemoradiotherapy was recommend-
ed to every patient.
Assessments and evaluations
Remission after induction chemothera-
py was assessed according to WHO cri-
teria by a dedicated head and neck radiol-
ogist. Follow-up visits were arranged ev-
ery 3–6 months for the first 2 years and 
biyearly thereafter. Toxicity during in-
duction chemotherapy was graded ac-
cording to the National Cancer Institute 
Common Terminology Criteria for Ad-
verse Events (CTCAE) version 4.0. Only 
grade 3 or higher toxicity was taken into 
account. Acute and late RT-related toxic-
ity was graded using the Radiation Ther-
apy Oncology Group (RTOG) Radiation 
Morbidity Scoring Criteria. Additionally, 
treatment interruptions during chemora-
diation and the time of feeding tube in si-
tu were calculated.
Statistical considerations
The primary objective of the study was to 
assess acute and late RT-related toxicity 
including treatment gaps during chemo-
radiotherapy; secondary objectives were 
response to induction chemotherapy, lo-
coregional recurrence-free survival (LR-
RFS), overall survival (OS), and relevant 
influencing factors for LRRFS and OS. 
Descriptive statistics included absolute 
and relative frequencies for categorical 
variables, and the median and range for 
quantitative variables. All time-to-event 
end points were calculated from the start 
of induction chemotherapy. Survival rates 
were calculated using the Kaplan–Meier 
product limit methodology. The influence 
of good response to induction chemother-
apy [complete remission (cR) and par-
tial remission (pR)] vs. no response (no 
change) on LRRFS and OS was compared 
using a two-sided log-rank test. Univar-
iate Cox regression analysis was used to 
study the influence of risk factors on LR-
RFS and OS. A p value of <0.05 was con-
sidered statistically significant. Statistical 
Tab. 1 Patient characteristics (n=40)
  n (%)
Age (years)
– Median (range) 58 (39–73)
ECOG performance status
– 0 or 1 32 (80)
– 2 8 (20)
Gender
– Female 9
– Male 31
Site
–Oral cavity 3 (7.5)
– Oropharynx 20 (50)
– Hypopharynx 5 (12.5)
– Larynx 7 (17.5)
– Other 5 (12.5)
T classificationa
– T0 (CUP) 2 (5)
– T1 0 (0)
– T2 2 (5)
– T3 11 (27.5)
– T4 25 (62.5)
N classificationa
– N0 3 (7.5)
– N1 7 (17.5)
– N2a 0 (0)
– N2b 15 (37.5)
– N2c 10 (25)
– N3 5 (12.5)
Tumor stagea
– III 3 (7.5)
– IVa 29 (72.5)
– IVb 7 (17.5)
– Recurrenceb 1 (2.5)
Neck dissection 4 (10)
Tumor volume (ml)
– Median (range) 65 (2–392)
Induction chemotherapy
– TPF 27 (67.5)
– Median cycles (range) 3 (1–5)
– TP/other Taxol-containing 
regimen
13 (32.5)
– Median cycles (range) 2 (1–4)
Concomitant chemotherapy (n=34)
– 3 cycles cisplatin 13 (38)
– 2 cycles cisplatin 11 (32)
– 1 cycle cisplatin 3 (9)
– Carboplatin 3 (9)
– Cetuximab 3 (9)
– None 1 (3)
TPF docetaxel, cisplatin, 5-FU, TP docetaxel, cispla-
tin, CUP cancer of unknown primary aAccording to 
the 2002 AJCC classification bParapharyngeal nodal 
recurrence after resection of tongue primary and 
neck dissection and RT
Tab. 2 Acute RT-related toxicity (n=33)
  Pre-RT dys-
phagia
Dysphagia Mucositis Dermatitis Maximum 
toxicity by 
patient
Grade 0 24 (73%) 2 (6%) 4 (12%) 1 (3%) 0
Grade 1 3 (9%) 0 7 (21%) 7 (21%) 1 (3%)
Grade 2 2 (6%) 9 (27%) 14 (43%) 20 (61%) 7 (21%)
Grade 3 4 (12%) 22 (67%) 7 (21%) 5 (15%) 24 (73%)
Grade 4 0 0 1 (3%) 0 1 (3%)
Tab. 3 Late RT-related toxicity (n=27)
  Xerostomia Dermatitis Dysphagia Bone/carti-
lage necrosis
Maximum 
toxicity by 
patient
Grade 0 9 (33%) 10 (37%) 12 (44%) 23 (85%) 3 (11%)
Grade 1 6 (22%) 12 (44%) 8 (30%) 0 3 (11%)
Grade 2 8 (30%) 4 (15%) 6 (22%) 0 12 (44%)
Grade 3 4 (15%) 1 (4%) 1 (4%) 0 5 (19%)
Grade 4 0 0 0 4 (15%) 4 (15%)
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analysis was performed using SPSS ver-
sion 17.0 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
Patient characteristics are summarized in 
. Tab. 1. Initial staging consisted of mag-
netic resonance imaging (MRI) or CT; 
21 patients additionally underwent posi-
tron emission tomography (PET)/CT. 
Three patients underwent neck dissec-
tion after induction chemotherapy, one 
patient before. The median follow-up for 
surviving patients was 21 months (range, 
2–53.0 months). The median tumor vol-
ume was 65 ml, with 75% of patients pre-
senting tumors larger than 30 ml.
Induction chemotherapy, 
toxicity, and response
During induction chemotherapy, 8 pa-
tients (20%) developed grade 3–4 toxicity, 
mainly neutropenia. One patient died be-
cause of a septic complication, 2 patients 
died of unknown reasons after two cycles 
of induction chemotherapy. Two patients 
showed a deterioration in general condi-
tion and were referred to palliative treat-
ment; 1 patient declined RT. Thus, 6 pa-
tients did not undergo definitive chemo-
radiotherapy (15%). Complete remission 
after induction chemotherapy was ob-
served in 4 out of 40 patients (10%), par-
tial remission in 27 patients (68%), no 
change in 8 patients (20%), and 1 pa-
tient was not assessable. Patients receiv-
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Abstract
Background. Induction chemotherapy fol-
lowed by definitive chemoradiotherapy is an 
intensified treatment approach for locally ad-
vanced squamous cell carcinoma of the head 
and neck (HNSCC) that might be associated 
with high rates of toxicity.
Materials and methods. The data of 40 con-
secutive patients who underwent induc-
tion chemotherapy with docetaxel-contain-
ing regimens followed by intensity-modu-
lated radiotherapy (IMRT) and concomitant 
systemic therapy for unresectable locally ad-
vanced HNSCC were retrospectively analyzed. 
Primary objectives were RT-related acute and 
late toxicity. Secondary objectives were re-
sponse to induction chemotherapy, locore-
gional recurrence-free survival (LRRFS), over-
all survival (OS), and influencing factors for 
LRRFS and OS.
Results. The median follow-up for sur-
viving patients was 21 months (range, 
2–53 months). Patients received a median of 
three cycles of induction chemotherapy fol-
lowed by IMRT to 72 Gy. Three patients died 
during induction chemotherapy and one dur-
ing chemoradiotherapy. Acute RT-related tox-
icity was of grade 3 and 4 in 72 and 3% of pa-
tients, respectively, mainly dysphagia and 
dermatitis. Late RT-related toxicity was main-
ly xerostomia and bone/cartilage necrosis 
and was of grade 3 and 4 in 15% of patients. 
One- and 2-year LRRFS and OS were 72 and 
49% and 77 and 71%, respectively.
Conclusion. Induction chemotherapy fol-
lowed by chemoradiotherapy using IMRT was 
associated with a high rate of severe acute 
and late RT-related toxicities in this select-
ed patient cohort. Four patients were lost be-
cause of fatal complications. Induction che-
motherapy did not compromise the delivery 
of full-dose RT; however, the use of three cy-
cles of concomitant cisplatin was impaired.
Keywords
Chemoradiotherapy · Induction 
chemotherapy · Radiotherapy · Head and 
neck cancer · Toxicity
Taxanhaltige Induktionschemotherapie gefolgt von definitiver Radiochemotherapie. 
Resultate von Patienten mit lokal fortgeschrittenen Kopf-Hals-Tumoren
Zusammenfassung
Hintergrund. Induktionschemotherapie ge-
folgt von definitiver kombinierter Radioche-
motherapie ist eine intensivierte Behand-
lungsstrategie bei Patienten mit lokal fort-
geschrittenen Plattenepithelkarzinomen 
der Kopf-Hals-Region, die mit hohen Toxi-
zitätsraten verbunden sein könnte.
Material und Methoden. Wir haben eine 
retrospektive Analyse von 40 aufeinander-
folgenden Patienten mit nichtoperablen, lo-
kal fortgeschrittenen Kopf-Hals-Tumoren 
durchgeführt, die eine docetaxelhaltige In-
duktionschemotherapie gefolgt von einer in-
tensitätsmodulierten RT (IMRT) kombiniert 
mit einer systemischen Therapie erhielten. 
Das primäre Interesse galt den strahlenthe-
rapieassoziierten Toxizitäten. Weitere Ziele 
stellten das Ansprechen auf Induktionsche-
motherapie, lokoregionäre Rezidivfreiheit 
(LRRFS) und Gesamtüberleben (OS) sowie da-
rauf bezogene Einflussfaktoren dar.
Ergebnisse. Der Median der Nachkontroll-
zeit betrug 21 Monate (2–53 Monate). 
Die Patienten erhielten median 3 Zyklen 
Induktions chemotherapie gefolgt von IMRT 
bis 72 Gy. Während der Induktionschemo-
therapie verstarben 3 Patienten, während der 
Radiochemotherapie 1 Patient. Akute RT-as-
soziierte Toxizitäten vom Grad 3 und 4 traten 
bei 72 bzw. 3% der Patienten auf, vor allem 
Dysphagie und Dermatitis. Späte RT-assozi-
ierte Toxizitäten, bei denen es sich bei jeweils 
15% der Patienten um Grad 3 und 4 handelte, 
betrafen Xerostomie und Knorpel-/Knochen-
nekrosen. Das LRRFS nach 1 bzw. 2 Jahren 
betrug 72 bzw 49%, das OS 77 bzw. 71%.
Schlussfolgerungen. Indiktionschemothe-
rapie gefolgt von Radiochemotherapie mit 
IMRT war in dieser definierten Patientenko-
horte mit einem hohen Anteil schwerer Toxi-
zitäten verbunden. Während der Behand-
lung verstarben 4 Patienten. Die Induktions-
chemotherapie schränkte die Durchführung 
der Radiotherapie nicht ein, die konkomitan-
te Gabe von 3 Zyklen Cisplatin war jedoch 
eingeschränkt.
Schlüsselwörter
Radiochemotherapie · 
Induktionschemotherapie · Strahlentherapie · 
Kopf-Hals-Tumoren · Toxizität
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ing three to five cycles of induction che-
motherapy had a significantly higher rate 
of cR/pR compared to patients with one 
to two cycles (Fisher’s exact test, p=0.03).
Chemoradiotherapy, RT-related 
toxicity, and outcome
The median time from the last cycle of in-
duction chemotherapy to the start of RT 
was 45 days (range, 0–203 days). One pa-
tient first refused RT and then started 
7 months after induction chemotherapy. 
Four patients had interruptions of RT re-
lated to acute toxicity of 5 days. One pa-
tient died during chemoradiotherapy be-
cause of a feeding tube-related infection 
after the first cycle of cisplatin.
Data for acute and late RT-related 
toxicity were available for 33 and 27 pa-
tients, respectively. The results are sum-
marized in . Tab. 2 and . Tab. 3. Eight 
patients (23%) received gastrostomy pri-
or to RT because of swallowing deficits, 
12 patients (35%) had prophylactic feed-
ing tube placement at the beginning of RT. 
The median time of feeding tube in situ 
was 12 months (range, 2–38 months).
Five patients experienced local recur-
rence; 1 a local tumor persistence, 2 mere-
ly regional recurrence, and 4 patients had 
both local and regional recurrence. The 
3 patients not undergoing chemoradio-
therapy were taken into account as tumor 
persistence. At 1 and 2 years, LRRFS was 
72, and 49%, respectively. The influence of 
risk factors on LRRFS is shown in . Fig. 1 
and . Tab. 4.
Four patients developed distant me-
tastasis 6, 7, 14, and 20 months after treat-
ment, respectively. All but one of these 
patients had an earlier locoregional re-
currence.
A total of 13 deaths were noted. Be-
sides 3 patients who died before under-
going chemoradiotherapy, 2 patients with 
deterioration of general condition under 
induction chemotherapy and 1 patient re-
fusing RT subsequently underwent pal-
liative therapy and eventually died of tu-
mor progression. One patient died dur-
ing chemoradiotherapy of a feeding tube 
complication and 6 patients died during 
follow-up, 5 because of tumor progres-
sion, 1 of pulmonary disease.
One- and 2-year OS was 77 and 
71%, respectively, with a median OS of 
34 months. The analysis of risk factors on 
OS is shown in . Fig. 2 and . Tab. 5.
Discussion
We identified considerable rates of RT-re-
lated acute and late toxicities after induc-
tion chemotherapy followed by chemora-
diotherapy in our selected patient cohort 
with unresectable locally advanced HN-
Fig. 1 9 Locoregion-
al recurrence-free sur-
vival of all patients (a) 
and stratified accord-
ing to tumor response 
after induction chemo-
therapy (b, c)
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SCC. Acute grade 3 dysphagia was pres-
ent in 67% of patients and grade 3 muco-
sitis in 21%. Very high rates of acute tox-
icity have been reported in an analysis of 
patients undergoing TPF induction che-
motherapy followed by 3D conformal 
chemoradiotherapy with grade 3 skin tox-
icity in 73% and grade 3 mucosal toxicity 
in 85% of patients [12]. The development 
of IMRT significantly reduced xerostomia 
when compared to 3D-CRT in a random-
ized controlled trial [13]. Recently, a large 
retrospective trial showed that both tech-
niques yielded the same locoregional con-
trol and overall survival but with signifi-
cantly less toxicity when using IMRT [14]. 
In a direct comparison of TPF induction 
followed by chemoradiotherapy vs. direct 
chemoradiotherapy, equal rates of grade 
3/4 dysphagia in 21% vs. 20% and muco-
sitis in 28% vs. 37% of patients were found 
[7], which are considerably lower than in 
our study. However, the RT technique 
was not stated and an uncommon score 
was used impairing direct comparison. In 
our study, all patients but one undergoing 
chemoradiotherapy completed RT as pre-
scribed. This compares favorably to TAX 
324, where 21% of patients in the TPF arm 
did not receive full RT [5].
To avoid toxicity-related treatment 
breaks, use of gastrostomy feeding tubes 
during irradiation of advanced HNSSC is 
standard in our institution, even though 
this procedure has been discussed contro-
versially [15]. Patients received pain med-
ication and dedicated skin care. When 
necessary, patients were hospitalized to 
administer i.v. fluids. In our cohort, on-
ly 4 patients (12%) had toxicity-related 
treatment interruptions of 5 days, known 
to be associated with decreased surviv-
al [16]. This is within the range of 10% 
found in conventional chemoradiothera-
py [17]. During chemoradiotherapy, 38% 
of the patients received three cycles of cis-
platin, 32% received two cycles. A retro-
spective analysis of patients treated by the 
same regimen found results of 5% receiv-
ing three cycles, 61% receiving two cycles, 
and 29% receiving one cycle of concur-
rent cisplatin [12]. These rates are consid-
erably lower than reported in the standard 
RTOG 91-11 study [18]. Induction chemo-
therapy thus seems to impair concomitant 
chemotherapy with cisplatin, but not the 
delivery of RT once started.
Data on late toxicity after induction 
chemotherapy followed by chemoradio-
therapy for HNSCC are sparse. Our rates 
of late RT-related toxicity of 44% grade 2, 
19% grade 3, and 15% grade 4 are compa-
rable with the data in other publications. 
Van Gestel et al. [19] described late toxici-
ty of any grade in 16 of 18 patients treated 
with induction chemotherapy followed by 
chemoradiotherapy, mainly xerostomia. 
In a long-term analysis of the TAX 324 tri-
Fig. 2 9 Overall sur-
vival of all patients (a) 
and stratified accord-
ing to tumor response 
after induction chemo-
therapy (b, c)
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al, only half of the surviving patients could 
be assessed for the surrogate parameter of 
presence of tracheotomy (7%) and feed-
ing tube dependency (3%) [20]. A recent 
long-term analysis after concurrent hy-
perfractionated RT vs. hyperfractionated 
RT alone found grade 3 dysphagia in 24% 
and grade 4 in 3% of patients in the com-
bined treatment arm [21]. In our patient 
cohort, osteoradionecrosis of the mandi-
ble and necrosis of laryngeal cartilage pre-
sented the most severe late toxicity. Surgi-
cal interventions like debridement or even 
resection and tracheotomy might become 
necessary, but were not observed in our 
patient cohort.
In our series after induction chemo-
therapy, we observed a cR in 10% of pa-
tients, pR in 68% of patients, and no 
change in 20% of patients. The TAX 324 
group reported a slightly higher overall re-
sponse rate after induction chemotherapy 
of 72% in the TPF group. The percentage 
of patients with a complete response was 
17% in the TPF group [5].
We found an LRRFS at 1 and 2 years 
of 72 and 49%, respectively. The OS rate 
was 77% at 1 year and 71% at 2 years, with 
median OS being 34 months. The TAX 
324 study group [5] found a median OS 
of 59 months and a 3 year-OS of 62% for 
stage 4 patients treated with TPF induc-
tion. PFS was 49% at 3 years. The phase 
II study of Paccagnella comparing induc-
tion chemotherapy vs. direct chemoradio-
therapy [7] suggested a prolonged OS of 
61% vs. 57% and PFS of 56% vs. 45% at 
2 years in favor of TPF induction. How-
ever, in the recently published abstracts of 
the DeCIDE and PARADIGM phase III 
trials comparing induction chemotherapy 
with direct chemoradiotherapy, no benefit 
in OS (75% vs. 73% at 24 months and 73% 
vs. 78% at 36 months) or PFS (67% vs. 
73% at 36 months) was found [8, 9]. The 
same applies for induction chemotherapy 
followed by surgery and adjuvant chemo-
radiotherapy [10]. The issue of tumor load 
as an independent risk factor for outcome 
in HNSCC has been shown in the litera-
ture [22] and was confirmed in our study 
(. Tab. 4). The relevance of induction 
chemotherapy with respect to gross tu-
mor volume remains unclear. Older phase 
III trials investigating the role of induction 
chemotherapy found no benefit for local 
control and OS, but a significant decrease 
in distant failure [23]. Distant metasta-
sis occurred in our collective mainly af-
ter locoregional recurrence in 10% of pa-
tients; one solely distant failure was seen 
(2.5%). The DeCIDE trial found a low-
er cumulative incidence of distant failure 
in the induction chemotherapy arm, but 
this did not translate into OS benefit. Pa-
tients treated with standard chemoradio-
therapy showed a rate of distant failure be-
tween 7% at 20 months [23] and 25.3% at 
3 years [17]. These data need careful inter-
pretation, as patients with an uncontrol-
lable locoregional recurrence are usually 
not screened for distant metastases.
In the current study, we found an OS 
benefit for patients with good response to 
induction chemotherapy (p=0.04), with a 
trend regarding locoregional control. Ka-
plan–Meier plots demonstrate a clear sep-
aration of the survival curves according to 
response on induction therapy. The better 
OS in spite of nonsignificant differences in 
LRRFS for good response might be relat-
ed to the fact that patients with good re-
mission had longer survival with palliative 
chemotherapy (4 patients) and RT (2 pa-
tients) The most important influence on 
Tab. 4 Univariate Cox regression analysis for risk factors influencing locoregional recur-
rence-free survival (n=40)
Risk factor HR CI p value
Age ≥58 years 0.2 0.04–0.8 0.02
Gender male 1.5 0.4–5.3 0.53
ECOG 2 8.2 2.2–30 0.01
T classification T4 1.9 0.6–5.5 0.27
Subsite hypopharynx 1.8 0.5–6.4 0.39
N classification N2c-N3 1.1 0.4–3.1 0.83
Tumor volume >65 ml 4.5 1.2–17.8 0.03
Induction chemo-
therapy 3–5 cycles
1.0 0.3–3.1 1.0
Response to induction 
chemotherapy no 
change
2.4 0.8–7.0 0.12
Concomitant chemo-
therapy other regimen
0.7 0.2–3.2 0.7
Total treatment time 
>20 weeksa
0.5 0.2–1.7 0.29
HR hazard ratio, CI 95% confidence interval aFor 33 patients completing therapy
Tab. 5 Univariate Cox regression analysis for risk factors influencing overall survival (n=40)
Risk factor HR CI p value
Age ≥58 years 0.75 0.23–2.5 0.63
Gender male 1.6 0.4–7.2 0.55
ECOG 2 4.3 1.4–13.2 0.01
T classification T4 3.5 0.77–16.3 0.11
Subsite hypopharynx 2.0 0.6–6.6 0.3
N classification N2c-N3 1.3 0.43–3.9 0.65
Tumor volume >65 ml 6.5 0.77–55.3 0.08
Induction chemo-
therapy 3–5 cycles
0.5 0.2–1.6 0.24
Response to induction 
chemotherapy no 
change
3.2 1.0–10.1 0.05
Concomitant chemo-
therapy other regimen
1.2 0.2–6.1 0.8
Total treatment time 
>20 weeksa
1.0 0.2–4.5 0.98
HR hazard ratio, CI 95% confidence interval aFor 33 patients completing therapy
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outcome was seen for performance score, 
stressing the importance of clinical pa-
tient evaluation. This aspect is well known 
from direct chemoradiation [24].
Remarkably, 3 patients (7%) died in the 
interval between induction chemotherapy 
and the start of RT with one death directly 
attributable to sepsis in neutropenia; 1 pa-
tient died during RT. Fewer fatal compli-
cations were reported in prospective trials 
[5, 7], which may be related to the strict-
er inclusion criteria concerning perfor-
mance score and comorbidity. Howev-
er, the DeCIDE trial showed three deaths 
(3.5%) during induction and nine (10%) 
during subsequent chemoradiation as op-
posed to four deaths in direct chemora-
diation [8].
Owing to the relatively short follow-up 
and the retrospective nature of this study, 
our results should be considered as the hy-
pothetic base for further studies with lon-
ger follow-up.
Conclusion
TPF induction chemotherapy followed 
by chemoradiotherapy outside a study 
protocol is associated with a high rate of 
acute and late RT-related toxicities. In our 
study 4 patients were lost because of fa-
tal complications, at least 1 of them with 
a direct link to chemotherapy-induced 
neutropenia. Induction chemotherapy 
did not compromise the delivery of full-
dose RT; however, the use of three cycles 
of concomitant cisplatin was impaired.
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